Download PDF
Semin Thromb Hemost 2019; 45(06): 629-637
DOI: 10.1055/s-0039-1693474
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients

Deborah Y. Park
1   Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio
,
Alok A. Khorana
2   Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio
› Author Affiliations
Further Information

Publication History

Publication Date:
26 July 2019 (online)

    Permissions and Reprints

Abstract

Venous thromboembolism (VTE) is a common complication of cancer occurring in up to one-fifth of cancer patients. The risk of VTE, which includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is increased up to seven-fold in patients with cancer. While the indications and contraindications to treatment for VTE patients with cancer parallel to those patients without cancer, the treatment of VTE is challenging for cancer patients who are three-fold more likely to have VTE recurrence than patients without cancer and who are also at increased risk of bleeding. While anticoagulant therapy is recommended for most cancer patients with VTE, some patients may benefit from alternative interventions, such as thrombolysis, thromboembolectomy, or placement of an inferior vena cava (IVC) filter. Recent data support the use of direct oral anticoagulants (DOACs) for treatment of cancer-associated VTE in select cancer patients and for primary prevention of thromboembolism in high-risk cancer patients. Individualized decision-making, keeping in consideration the patient's risk for thrombotic and bleeding events is essential.

Keywords

cancer-associated venous thromboembolism - thrombosis - anticoagulation
 

  • References

  • 1 Prandoni P, Lensing AWA, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 2 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedGoogle Scholar
  • 3 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 9 (07) e1001275 . Doi: 10.1371/journal.pmed.1001275
    CrossrefPubMedGoogle Scholar
  • 4 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedGoogle Scholar
  • 5 Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24 (03) 484-490
    CrossrefPubMedGoogle Scholar
  • 6 Lip GYH, Chin BSP, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3 (01) 27-34
    CrossrefPubMedGoogle Scholar
  • 7 Sallah S, Husain A, Sigounas V. , et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 2004; 10 (21) 7238-7243
    CrossrefPubMedGoogle Scholar
  • 8 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18 (17) 3078-3083
    CrossrefPubMedGoogle Scholar
  • 9 Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am J Med 2001; 110 (07) 515-519
    CrossrefPubMedGoogle Scholar
  • 10 Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001; 111 (04) 270-273
    CrossrefPubMedGoogle Scholar
  • 11 Lee AYY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005; 128 (03) 291-302
    CrossrefPubMedGoogle Scholar
  • 12 Monreal M, Falgá C, Valdés M. , et al; Riete Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4 (09) 1950-1956
    CrossrefPubMedGoogle Scholar
  • 13 Lee AYY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 14 Lee AYY, Rickles FR, Julian JA. , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23 (10) 2123-2129
    CrossrefPubMedGoogle Scholar
  • 15 Lee AYY, Kamphuisen PW, Meyer G. , et al; CATCH Investigators. tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 16 Thein KZ, Tijani L, Oo TH. Low- molecular weight heparins (LMWH) versus vitamin k antagonists (VKAS) in the treatment and secondary prevention of cancer-associated venous thromboembolism (VTE): a systematic review and meta-analysis of randomized controlled trials (RCTS). Blood 2016; 128 (22) 1180
    CrossrefPubMedGoogle Scholar
  • 17 Kahale LA, Hakoum MB, Tsolakian IG. , et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 2018; 6: CD006650 . Doi: 10.1002/14651858.CD006650.pub5
    PubMedGoogle Scholar
  • 18 Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (02) 475-483
    CrossrefPubMedGoogle Scholar
  • 19 Prins MH, Lensing AW, Bauersachs R. , et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (01) 21 . Doi: 10.1186/1477-9560-11-21
    CrossrefPubMedGoogle Scholar
  • 20 Schulman S, Goldhaber SZ, Kearon C. , et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114 (01) 150-157
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 22 Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res 2019; 173: 158-163
    CrossrefPubMedGoogle Scholar
  • 23 Khorana AA, Noble S, Lee AYY. , et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (09) 1891-1894
    CrossrefPubMedGoogle Scholar
  • 24 Mantha S, Laube E, Miao Y. , et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 2017; 43 (02) 166-171
    CrossrefPubMedGoogle Scholar
  • 25 Ross JA, Miller MM, Rojas Hernandez CM. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis. Thromb Res 2017; 150: 86-89
    CrossrefPubMedGoogle Scholar
  • 26 Lyman GH, Khorana AA, Kuderer NM. , et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17) 2189-2204
    CrossrefPubMedGoogle Scholar
  • 27 Samuelson Bannow BT, Lee A, Khorana AA. , et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (06) 1246-1249
    CrossrefPubMedGoogle Scholar
  • 28 White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999; 107 (05) 414-424
    CrossrefPubMedGoogle Scholar
  • 29 Trujillo-Santos J, Nieto JA, Tiberio G. , et al; RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. findings from the RIETE Registry. Thromb Haemost 2008; 100 (03) 435-439
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Kooiman J, den Exter PL, Cannegieter SC. , et al. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost 2013; 11 (11) 1968-1976
    CrossrefPubMedGoogle Scholar
  • 31 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124 (15) 2450-2458
    PubMedGoogle Scholar
  • 32 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149 (02) 315-352 . Doi: 10.1016/j.chest.2015.11.026
    CrossrefPubMedGoogle Scholar
  • 33 Heit JA, Lahr BD, Petterson TM, Bailey KR, Ashrani AA, Melton III LJ. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood 2011; 118 (18) 4992-4999
    PubMedGoogle Scholar
  • 34 Francis CW, Kessler CM, Goldhaber SZ. , et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13 (06) 1028-1035
    CrossrefPubMedGoogle Scholar
  • 35 Louzada ML, Carrier M, Lazo-Langner A. , et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (04) 448-454
    CrossrefPubMedGoogle Scholar
  • 36 Kearon C, Akl EA, Comerota AJ. , et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S-e496S
    CrossrefPubMedGoogle Scholar
  • 37 Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA 2014; 311 (07) 717-728
    CrossrefPubMedGoogle Scholar
  • 38 Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014; 123 (12) 1794-1801
    CrossrefPubMedGoogle Scholar
  • 39 Linkins L-A, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139 (11) 893-900
    Google Scholar
  • 40 Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 2014; 127 (01) 82-6.e1
    CrossrefPubMedGoogle Scholar
  • 41 Connors JM. Prophylaxis against venous thromboembolism in ambulatory patients with cancer. N Engl J Med 2014; 370 (26) 2515-2519
    CrossrefPubMedGoogle Scholar
  • 42 Kucher N, Spirk D, Baumgartner I. , et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the swiss venous thromboembolism registry (SWIVTER). Ann Oncol 2010; 21 (05) 931-935
    CrossrefPubMedGoogle Scholar
  • 43 Agnelli G, Caprini JA. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. J Surg Oncol 2007; 96 (03) 265-272
    CrossrefPubMedGoogle Scholar
  • 44 Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 2009; 115 (24) 5637-5650
    CrossrefPubMedGoogle Scholar
  • 45 Bergqvist D, Agnelli G, Cohen AT. , et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346 (13) 975-980
    CrossrefPubMedGoogle Scholar
  • 46 Rasmussen MS, Jorgensen LN, Wille-Jørgensen P. , et al; FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4 (11) 2384-2390
    CrossrefPubMedGoogle Scholar
  • 47 Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P. ; CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8 (06) 1223-1229
    CrossrefPubMedGoogle Scholar
  • 48 Browne AM, Cronin CG, English C, NiMhuircheartaigh J, Murphy JM, Bruzzi JF. Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol 2010; 5 (06) 798-803
    CrossrefPubMedGoogle Scholar
  • 49 Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 2007; 356 (14) 1438-1444
    CrossrefPubMedGoogle Scholar
  • 50 Dobromirski M, Cohen AT. How I manage venous thromboembolism risk in hospitalized medical patients. Blood 2012; 120 (08) 1562-1569
    PubMedGoogle Scholar
  • 51 Streiff MB, Holmstrom B, Angelini D. , et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw 2018; 16 (11) 1289-1303
    CrossrefPubMedGoogle Scholar
  • 52 Farge D, Debourdeau P, Beckers M. , et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11 (01) 56-70
    CrossrefPubMedGoogle Scholar
  • 53 Patell R, Rybicki L, McCrae KR, Khorana AA. Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. Am J Hematol 2017; 92 (06) 501-507
    CrossrefPubMedGoogle Scholar
  • 54 Parker A, Peterson E, Lee AYY. , et al. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. J Thromb Haemost 2018; 16 (07) 1321-1326
    CrossrefPubMedGoogle Scholar
  • 55 Agnelli G, Gussoni G, Bianchini C. , et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10 (10) 943-949
    CrossrefPubMedGoogle Scholar
  • 56 Agnelli G, George DJ, Kakkar AK. , et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (07) 601-609
    CrossrefPubMedGoogle Scholar
  • 57 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedGoogle Scholar
  • 58 Mandala M, Clerici M, Corradino I. , et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol 2012; 23 (06) 1416-1421
    CrossrefPubMedGoogle Scholar
  • 59 Ay C, Dunkler D, Marosi C. , et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
    CrossrefPubMedGoogle Scholar
  • 60 Angelini D, Khorana AA. Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease. Semin Thromb Hemost 2017; 43 (05) 469-478
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Pabinger I, van Es N, Heinze G. , et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5 (07) e289-e298
    Google Scholar
  • 62 Pelzer U, Opitz B, Deutschinoff G. , et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the conko-004 trial. J Clin Oncol 2015; 33 (18) 2028-2034
    CrossrefPubMedGoogle Scholar
  • 63 Maraveyas A, Waters J, Roy R. , et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48 (09) 1283-1292
    CrossrefPubMedGoogle Scholar
  • 64 Khorana AA, Yannicelli D, McCrae KR. , et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?. Thromb Res 2016; 145: 51-53
    CrossrefPubMedGoogle Scholar
  • 65 Khorana AA, Vadhan-Raj S, Kuderer NM. , et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the Cassini trial. Rationale and design of the CASSINI trial. Thromb Haemost 2017; 117 (11) 2135-2145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Carrier M, Abou-Nassar K, Mallick R. , et al. AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
    CrossrefPubMedGoogle Scholar
  • 67 Khorana AA, Soff GA, Kakkar AK. , et al. Rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI). Blood 2018; 132 (Suppl. 01) LBA-1-LBA-1
    CrossrefPubMedGoogle Scholar